Survival Outcomes of Patients With Pulmonary LCNEC Clinical Trial
Official title:
Overall Survival and Progression Free Survival of Patients With Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to the analysis. Patients were treated with radical, palliative or symptomatic intension between 2002-2018 in central and north-eastern centres in Poland. The group of patients consists of 47 women (36%) and 85 men (64%). Ratio of women to men is 1:1,81. The observation period ranged from 0 to 192 months.
This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to
the analysis. Patients were treated with radical, palliative or symptomatic intension between
2002-2018 in central and north-eastern centres in Poland. The group of patients consists of
47 women (36%) and 85 men (64%). Ratio of women to men is 1:1,81. The observation period
ranged from 0 to 192 months.
For all patients included to the analysis, the clinical stage was estimated according to TNM
Classification of Malignant Tumours - UICC from 2017. The degree of pathomorphic stage (pTNM)
was assessed in 60 patients treated with intention to treat (ITT), which is 45% of the total
population.
The degree of clinical stage (cTNM) was assessed in 72 patients based on the imaging
examinations (including PET, CT, MRI, bone scintigraphy, etc.) and fine needle aspiration
biopsy (FNA) (including EBUS, with pathological confirmation of LCNEC, which is 55% of the
total population.
The clinical stage (cTNM) was used in case of patients disqualified from radical surgery due
to: advanced disease, contraindications to surgery, no patient's consent for treatment.
;